Genmab moves further away from ‘naked’ antibodies with mix-and-match modality deals

With capital at the ready, Genmab is looking to modality mixing deals as a path to next-generation biologics that outshine traditional antibody therapies. Favoring partnerships over M&A, the Danish company has made commercial rights a priority, and put alternative immune cell engagers and delivery strategies at the top of its wishlist. 

“We’re sitting on $2.9 billion of cash, so we can try a few of these options to see which are best,” Genmab A/S (NASDAQ:GMAB; CSE:GMAB) CEO Jan van de Winkel told BioCentury. ...